Resolution of Late Steroid-Responsive Nephrotic Syndrome in a Patient with Alport Syndrome Treated with Atorvastatin
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53730#.VNB6JCzQrzE
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53730#.VNB6JCzQrzE
Affiliation(s)
1Graduate Institute of Basic Medicine, Fu Jen Catholic University, Taipei, Taiwan.
2Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
3Department of Anatomic Pathology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
2Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
3Department of Anatomic Pathology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
ABSTRACT
Experimental
and clinical studies have pointed out the lipid-induced renal damage,
and statins may have pleiotropic effects on renoprotection. We reported a
girl with X-linked Alport syndrome whose late steroid-responsive
nephrotic syndrome (NS) was resolved by atorvastatin. She had been in a
nephrotic condition despite of prednisone therapy 60 mg/day for 8 weeks.
Renal biopsy dispicted extreme foamy appearance of tubular epithelial
cells with detachment led to luminal obliteration. Atorvastatin was
started on the ninth week of prednisone therapy due to severe
hypercholesterolemia. Partial remission of NS was dramatically achieved
with unchanged dosage of prednisone at the end of the twelfth week. Our
case provides a pathology-based evidence to support the use of statins
in profoundly hyperlipidemic patients with NS. In patients with NS and
profound hyperlipidemia, early initiation of statin therapy is required
in combination with immunosuppressive therapy.
Cite this paper
References
Chang,
J. , Lin, W. and Tsai, C. (2015) Resolution of Late Steroid-Responsive
Nephrotic Syndrome in a Patient with Alport Syndrome Treated with
Atorvastatin. Open Journal of Pediatrics, 5, 12-16. doi: 10.4236/ojped.2015.51003.
| [1] | Kiss, E., Kranzlin, B., Wagenblaβ, K., Bonrouhi, M., Thiery, J., Grone E., Nordstrom, V., Teupser, D., Gretz, N., Malle, E. and Grone, H.J. (2013) Lipid Droplet Accumulation Is Associated with an Increase in Hyperglycemia-Induced Renal Damage: Prevention by Liver X Receptors. The American Journal of Pathology, 182, 727-741. http://dx.doi.org/10.1016/j.ajpath.2012.11.033 |
| [2] | Trevisan, R., Dodesini, A.R. and Lepore, G. (2003) Lipids and Renal Disease. Journal of the American Society of Nephrology, 17, S145-S147. http://dx.doi.org/10.1681/ASN.2005121320 |
| [3] | Hattori, M., Chikamoto, H., Akioka, Y., Nakakura, H., Ogino, D., Matsunaga, A., Fukazawa, A., Miyakawa, S., Khono, M., Kawaguchi, H. and Ito, K. (2003) A Combined Low-Density Lipoprotein Apheresis and Prednisone Therapy for Steroid-Resistant Primary Focal Segmental Glomerulosclerosis in Children. American Journal of Kidney Diseases, 42, 1121-1130. http://dx.doi.org/10.1053/j.ajkd.2003.08.012 |
| [4] | Ito, S., Machida, H., Inaba, A., Harada, T., Okuyama, K., Nakamura, T., Aihara, Y. and Yokota, S. (2007) Amelioration of Steroids and Cyclosporine-Resistant Nephrotic Syndrome by Pravastatin. Pediatric Nephrology, 22, 603-606. http://dx.doi.org/10.1007/s00467-006-0371-4 |
| [5] | Prescott
Jr., W.A., Streetman, D.A. and Streetman, D.S. (2004) The Potential
Role of HMG-CoA Reductase Inhibitors in Pediatric Nephrotic Syndrome.
Annals of Pharmacotherapy, 38, 2105-2114. http://dx.doi.org/10.1345/aph.1D587 |
| [6] | Sanjad, S.A., Al-Abbad, A. and Al-Shorafa S. (1997) Management of Hyperlipidemia in Children with Refractory Nephrotic Syndrome: The Effect of Statin Therapy. The Journal of Pediatrics, 130, 470-474. http://dx.doi.org/10.1016/S0022-3476(97)70213-0 |
| [7] | Jiang, T., Wang, Z., Proctor, G., Moskowitz, S., Liebman, S.E., Rogers, T., Lucia, M.S., Li J. and Levi, M. (2005) Diet-Induced Obesity in C57BL/6J Mice Causes Increased Renal Lipid Accumulation and Glomerulosclerosis via a Sterol Regulatory Element-Binding Protein-1c-Dependent Pathway. The Journal of Biological Chemistry, 280, 32317-32325. http://dx.doi.org/10.1074/jbc.M500801200 |
| [8] | Gotoh, K., Masaki, T., Chiba, S., Ando, H., Fujiwara, K., Shimasaki, T., Tawara, Y., Toyooka, I., Shiraishi, K., Mitsutomi, K., Anai, M., Itateyama, E., Hiraoka, J., Aoki, K., Fukunaga, N., Nawata, T. and Kakuma, T. (2013) Effects of Hydrophilic Statins on Renal Tubular Lipid Accumulation in Diet-Induced Obese Mice. Obesity Research & Clinical Practice, 7, e342-e352. http://dx.doi.org/10.1016/j.orcp.2013.04.001 |
| [9] | Eller, P., Eller, K., Wolf, A.M., Reinstadler, S.J., Tagwerker, A., Patsch, J.R., Mayer, G. and Rosenkranz, A.R. (2010) Atorvastatin Attenuates Murine Anti-Glomerular Basement Membrane Glomerulonephritis. Kidney International, 77, 428-435. http://dx.doi.org/10.1038/ki.2009.478 |
| [10] | Fujita, E., Shimizu, A., Masuda, Y., Kuwahara, N., Arai, T., Nagasaka, S., Aki, K., Mii, A., Natori, Y., Iino, Y., Katayama, Y. and Fukuda, Y. (2010) Statin Attenuates Experimental Anti-Glomerular Basement Membrane Glomerulonephritis Together with the Augmentation of Alternatively Activated Macrophages. The American Journal of Pathology, 177, 1143-1154. http://dx.doi.org/10.2353/ajpath.2010.090608 |
| [11] | Bussolati, B., Deregibus, M.C., Fonsato, V., Doublier, S., Spatola, T., Procida, S., Di Carlo, F. and Camussi, G. (2005) Statins Prevent Oxidized LDL-Induced Injury of Glomerular Podocytes by Activating the Phosphatidylinositol 3-Kinase/AKT-Signaling Pathway. Journal of the American Society of Nephrology, 16, 1936-1947. http://dx.doi.org/10.1681/ASN.2004080629 |
| [12] | Chu, G., Jia, R. and Yang, D. (2006) Fluvastatin Prevents Oxidized Low-Density Lipoprotein-Induced Injury of Renal Tubular Epithelial Cells by Inhibiting the Phosphatidylinositol 3-Kinase/Akt-Signaling Pathway. Journal of Nephrology, 19, 286-295. |
| [13] | Steffens,
S. and Mach, F. (2006) Drug Insight: Immunomodulatory Effects of
Statins—Potential Benefits for Renal Patients? Nature Clinical Practice
Nephrology, 2, 378-387. http://dx.doi.org/10.1038/ncpneph0217 |
| [14] | Stein, E.A. (2007) Statins and Children: Whom Do We Treat and When? Circulation, 116, 594-595. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.717777 |
| [15] | Vuorio, A., Kuoppala, J., Kovanen, P.T., Humphries, S.E., Strandberg, T., Tonstad, S. and Gylling, H. (2010) Statins for Children with Familial Hypercholesterolemia. Cochrane Database of Systematic Reviews, 7, CD006401. |
| [16] | Prescott
Jr., W.A., Streetman, D.A. and Streetman, D.S. (2004) The Potential
Role of HMG-CoA Reductase Inhibitors in Pediatric Nephrotic Syndrome.
Annals of Pharmacotherapy, 38, 2105-2114. http://dx.doi.org/10.1345/aph.1D587 eww150203lx |
评论
发表评论